RE:RE:RE:RE:RE:RE:RE:RE:RE:Toprol-XL Contract Renewalbiggerr wrote: at least it's very close to the bottom now, it's not like buying it at $7 and going all the way down to $2 for gad sake
Oh yeah? You sure about that bottom?
Any sort of technical assessment to a price should have some sound reasoning. There is no objective reasoning as to ARLZ being at a bottom.
Give it one more month before Q1 readouts. Remember: Yosprala sold through Q1 2017. ARLZ just cut the Yosprala sales force after Q1........ you think that's a bullish signal?
Furthermore, if they want to completely de-risk the price and take it to cash, we'll be below $1. At that point, it's on Zontivity. No mention either what the company intends to do with their Canadian/European approval for Yosprala. If it was lackluster in performance, the question is why would you go ahead for global commercialization. And, if they decide not to go with global commercialization after having said they would (i.e.: revoking it... though, not sure what likelihood is of this), what do you think that does to the price?
In short (no pun intended), still far too many risks to call the confident assertion of a bottom. Lots of bottom callers got burned in the $2's just after Q4 results.